Document Detail


Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience.
MedLine Citation:
PMID:  23292836     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed. Out of 93960 GU cancer patients treated in MD Anderson (cervix cancer 13,289, ovarian cancer 13,126, bladder cancer 11,834, prostate cancer 41,830, and kidney 13,881), 31 cases (0.03 %) of GU cancer with LM were identified in MD Anderson Cancer Center (MDACC) between 1978 and 2011. Eight patients had bladder cancer, 4 had cervical cancer, 4 had renal cancer, 8 had ovarian cancer and 7 had prostate cancer. Mean age of diagnosis of cancer was 55.9 ± 11.7 (range 20-74). Mean time from primary diagnosis to LM diagnosis was 141.46 ± 244 weeks (range 0.43-409.57). Median survival after LM diagnosis was 15.7 weeks (range 0.85-142.57). The patients presented with multiple signs and symptoms. Although rare-LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits.
Authors:
Shlomit Yust-Katz; Samuel Mathis; Morris D Groves
Related Documents :
23288346 - A systematic review of elastography, electrical impedance scanning, and digital infrare...
23088926 - Accuracy of colposcopy management to detect cin3 and invasive cancer in women with abno...
7501536 - Outcomes that provide evidence of change in cancer pain management.
23674896 - Potential role of new anticoagulants for prevention and treatment of venous thromboembo...
3292776 - Update in cancer chemotherapy: genitourinary tract cancer, part 6: cancer of the uterus...
21653646 - Genetically lowered microsomal epoxide hydrolase activity and tobacco-related cancer in...
Publication Detail:
Type:  Journal Article     Date:  2013-01-05
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  429     Citation Subset:  IM    
Affiliation:
Department of Neuro-Oncology Houston, Unit 431, The University of Texas MD Anderson Cancer Center, PO Box 301402, Houston, TX, USA, Syust@mdanderson.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic significance of BRCA1 expression in gastric cancer.
Next Document:  Clinicopathologic significance of ?-catenin and matrix metalloproteinase-2 expression in non-small c...